Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Merck & Co.
Biotech
Pyxis' shares fall on lukewarm early ADC results in solid tumors
While one might expect a positive readout from a biotech’s lead asset to boost stock prices, Pyxis Oncology’s shares tell a different story.
Fraiser Kansteiner
Nov 21, 2024 2:30pm
Biophama VC, deal values and exits all rise in Q3: Pitchbook
Nov 20, 2024 6:15am
Merck pays $588M for bispecific to defend Keytruda’s kingdom
Nov 14, 2024 7:45am
Arcus drops promising data on HIF-2a candidate in kidney cancer
Oct 24, 2024 2:48pm
Merck snaps up preclinical DNA biotech for $1.3B biobucks
Oct 23, 2024 7:05am
Merck-Gilead long-acting oral combo suppresses HIV for 48 weeks
Oct 21, 2024 5:06am
